Intralipid (Soya Oil, Purified)

The soybean oil provides a source of long‑chain triglycerides that are hydrolyzed by lipoprotein lipase after infusion. The resulting free fatty acids and glycerol are used for cellular energy production, membrane synthesis, and as precursors for essential fatty acids that the body cannot synthesize.

The dose of Intralipid is individualized. The prescribing clinician determines the volume and infusion rate based on the patient’s caloric needs, weight, baseline triglyceride levels, and overall clinical condition. No fixed regimen is provided in public information.

Safety data for Intralipid in pregnancy and lactation are limited. Because it is a parenteral nutrition product, it may be used when the benefits outweigh potential risks, but the decision should be made by the treating physician in consultation with obstetric specialists.

To order Intralipid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Intralipid is a soybean‑oil based emulsion, offering a balanced profile of omega‑6 and omega‑3 fatty acids. Compared with fish‑oil or mixed‑oil formulations, it provides a higher proportion of linoleic acid and is widely used in Europe. Choice of product depends on patient‑specific factors such as lipid tolerance, inflammatory status and clinician preference.

Intralipid must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, inspect the container for any signs of separation or discoloration and allow the emulsion to reach room temperature if required by the infusion protocol.

Intralipid is administered intravenously as an emulsion. It is typically infused through a dedicated line or compatible IV set, following aseptic technique. The infusion rate is set by the prescriber and may be adjusted based on patient tolerance, triglyceride monitoring and overall caloric goals.

Serious risks include anaphylactic reactions, acute respiratory distress syndrome, and severe hypertriglyceridemia that can lead to pancreatitis. Monitoring of triglyceride levels, liver function and respiratory status is essential, especially in patients receiving high‑dose or prolonged therapy.

Intralipid should be avoided in individuals with known hypersensitivity to soy, egg proteins, or any component of the emulsion. It is also contraindicated in patients with severe hyperlipidemia, uncontrolled sepsis, or those who have experienced previous severe infusion reactions.